Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice.

Hypertension and its complications represent leading causes of morbidity and mortality. Although the cause of hypertension is unknown in most patients, genetic factors are recognized as contributing significantly to an individual's lifetime risk of developing the condition. Here, we investigated the role of the G protein regulator phosducin (Pdc) in hypertension. Mice with a targeted deletion of the gene encoding Pdc (Pdc-/- mice) had increased blood pressure despite normal cardiac function and vascular reactivity, and displayed elevated catecholamine turnover in the peripheral sympathetic system. Isolated postganglionic sympathetic neurons from Pdc-/- mice showed prolonged action potential firing after stimulation with acetylcholine and increased firing frequencies during membrane depolarization. Furthermore, Pdc-/- mice displayed exaggerated increases in blood pressure in response to post-operative stress. Candidate gene-based association studies in 2 different human populations revealed several SNPs in the PDC gene to be associated with stress-dependent blood pressure phenotypes. Individuals homozygous for the G allele of an intronic PDC SNP (rs12402521) had 12-15 mmHg higher blood pressure than those carrying the A allele. These findings demonstrate that PDC is an important modulator of sympathetic activity and blood pressure and may thus represent a promising target for treatment of stress-dependent hypertension.

[1]  R. Langenbach,et al.  Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse , 1995, Cell.

[2]  H. Hamm,et al.  Phosducin‐like protein acts as a molecular chaperone for G protein βγ dimer assembly , 2005 .

[3]  Stefan Offermanns,et al.  G12-G13–LARG–mediated signaling in vascular smooth muscle is required for salt-induced hypertension , 2008, Nature Medicine.

[4]  S. E. Brodie New York, New York, USA , 1996 .

[5]  B. Obermaier,et al.  Phosducin is a protein kinase A-regulated G-protein regulator , 1992, Nature.

[6]  E. Antman,et al.  Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. , 2007, Circulation.

[7]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[8]  R. Karas,et al.  Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure , 2003, Nature Medicine.

[9]  P. Guyenet The sympathetic control of blood pressure , 2006, Nature Reviews Neuroscience.

[10]  R. Victor,et al.  Sympathetic neural mechanisms in human hypertension , 2008, Current hypertension reports.

[11]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[12]  T. C. Janeway The clinical study of blood-pressure : , 2009 .

[13]  L Kruglyak,et al.  Parametric and nonparametric linkage analysis: a unified multipoint approach. , 1996, American journal of human genetics.

[14]  C. Craft,et al.  Interaction of phosducin and phosducin isoforms with a 26S proteasomal subunit, SUG1. , 1998, Molecular vision.

[15]  M. Lohse,et al.  SUMO-1 Controls the Protein Stability and the Biological Function of Phosducin* , 2006, Journal of Biological Chemistry.

[16]  P. Veinante,et al.  Afferents to the GABAergic tail of the ventral tegmental area in the rat , 2009, The Journal of comparative neurology.

[17]  B. Kobilka,et al.  Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission , 1999, Nature.

[18]  M. Esler,et al.  The sympathetic system and hypertension. , 2000, American journal of hypertension.

[19]  Marcia M. Nizzari,et al.  Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels , 2007, Science.

[20]  T. Hudson,et al.  Quantitative founder-effect analysis of French Canadian families identifies specific loci contributing to metabolic phenotypes of hypertension. , 2005, American journal of human genetics.

[21]  S. Neubauer,et al.  Heterozygous alpha 2C-adrenoceptor-deficient mice develop heart failure after transverse aortic constriction. , 2007, Cardiovascular research.

[22]  M. Seldin,et al.  Rat pineal gland phosducin: cDNA isolation, nucleotide sequence, and chromosomal assignment in the mouse. , 1991, Genomics.

[23]  I. Oshima,et al.  Melatonin Content of the Pineal Gland in Different Mouse Strains , 1989, Journal of pineal research.

[24]  P. V. van Haastert,et al.  The Phosducin-Like Protein PhLP1 Is Essential for Gβγ Dimer Formation in Dictyostelium discoideum , 2005, Molecular and Cellular Biology.

[25]  A. Cowley The genetic dissection of essential hypertension , 2006, Nature Reviews Genetics.

[26]  H. Krum,et al.  Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. , 2005, Archives of internal medicine.

[27]  G. Abecasis,et al.  A general test of association for quantitative traits in nuclear families. , 2000, American journal of human genetics.

[28]  J. Johnston,et al.  Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II , 1995, Nature.

[29]  N. Schork,et al.  Identification of Hypertension-Related QTLs in African American Sib Pairs , 2002, Hypertension.

[30]  Robert J. Lefkowitz,et al.  Seven-transmembrane-spanning receptors and heart function , 2002, Nature.

[31]  L. Meinel,et al.  Vascular Hypertrophy and Increased P70S6 Kinase in Mice Lacking the Angiotensin II AT2 Receptor , 2001, Circulation.

[32]  Andrew Bohm,et al.  Crystal Structure at 2.4 Å Resolution of the Complex of Transducin βγ and Its Regulator, Phosducin , 1996, Cell.

[33]  M. Sokolov,et al.  Phosducin Facilitates Light-driven Transducin Translocation in Rod Photoreceptors , 2004, Journal of Biological Chemistry.

[34]  I. Llewellyn-Smith,et al.  Neurochemistry of nerve fibers apposing sympathetic preganglionic neurons activated by sustained hypotension , 2002, The Journal of comparative neurology.

[35]  M. Lohse,et al.  Phosducin-like Protein Regulates G-Protein βγ Folding by Interaction with Tailless Complex Polypeptide-1α , 2005, Journal of Biological Chemistry.

[36]  G. Nagy,et al.  Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. , 2003, Molecular endocrinology.

[37]  Heinz Bönisch,et al.  Comparison of in vitro and in vivo reference genes for internal standardization of real-time PCR data. , 2006, BioTechniques.

[38]  Brian K. Kobilka,et al.  Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice , 1995, Nature.

[39]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[40]  E. Ritz Total cardiovascular risk management. , 2007, The American journal of cardiology.

[41]  Tianxin Yang,et al.  Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice. , 2005, American journal of physiology. Renal physiology.

[42]  S. Lorkowski,et al.  Cloning, cellular localization, genomic organization, and tissue-specific expression of the TGFbeta1-inducible SMAP-5 gene. , 2005, Gene.

[43]  Remo Guidieri Res , 1995, RES: Anthropology and Aesthetics.

[44]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[45]  T. Ogihara,et al.  Identification of Hypertension-Susceptibility Genes and Pathways by a Systemic Multiple Candidate Gene Approach: The Millennium Genome Project for Hypertension , 2008, Hypertension Research.

[46]  W. Wetsel,et al.  Anovulation in cyclooxygenase-2-deficient mice is restored by prostaglandin E2 and interleukin-1beta. , 1999, Endocrinology.

[47]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[48]  I. Rodriguez,et al.  Natural melatonin 'knockdown' in C57BL/6J mice: rare mechanism truncates serotonin N-acetyltransferase. , 1998, Brain research. Molecular brain research.

[49]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[50]  H. Hamm,et al.  Phosducin-like protein acts as a molecular chaperone for G protein betagamma dimer assembly. , 2005, The EMBO journal.